Clinical and electrocardiography changes in patients treated with capecitabine
- PMID: 21997165
- DOI: 10.1159/000331645
Clinical and electrocardiography changes in patients treated with capecitabine
Abstract
Background: We aimed to identify the incidence of cardiac events with capecitabine treatment.
Methods: The study included 52 patients (median age 59 years) with cancer treated at our Medical Oncology Clinic between 2009 and 2010. Cardiac events from capecitabine treatment were classified into 4 groups: cardiac symptoms, physical signs, electrocardiography (ECG) findings, and severe adverse cardiac effects.
Results: The patients received either single-agent capecitabine or a combination chemotherapy including capecitabine. After initiation of capecitabine, 18 patients (34.6%) had new onset cardiovascular symptoms, 6 (11.5%) had new onset physical signs and 17 (32.6%) had new onset ECG findings. New onset ECG findings included prolonged corrected QT interval (n = 10, 19.2%) and prolonged PR interval (n = 3, 5.8%). Severe adverse capecitabine-induced cardiac side effects were observed in 5.8% of the patients, but none of the patients had myocardial infarction or died.
Conclusion: Cardiac events are not rare during capecitebine treatment and patients should be followed closely to avoid cardiac morbidity and mortality.
Copyright © 2011 S. Karger AG, Basel.
Similar articles
-
Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina.Intern Med J. 2010 Apr;40(4):303-7. doi: 10.1111/j.1445-5994.2009.02144.x. Intern Med J. 2010. PMID: 20529041
-
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.J Oncol Pharm Pract. 2012 Mar;18(1):140-7. doi: 10.1177/1078155210390255. J Oncol Pharm Pract. 2012. PMID: 22392964
-
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?Cardiology. 2010;116(1):42-4. doi: 10.1159/000313517. Epub 2010 Apr 29. Cardiology. 2010. PMID: 20431291
-
Capecitabine: a review.Clin Ther. 2005 Jan;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. Clin Ther. 2005. PMID: 15763604 Review.
-
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.Clin Breast Cancer. 2011 Dec;11(6):349-56. doi: 10.1016/j.clbc.2011.06.005. Clin Breast Cancer. 2011. PMID: 21856245 Review.
Cited by
-
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.Cancer Commun (Lond). 2018 May 11;38(1):22. doi: 10.1186/s40880-018-0292-1. Cancer Commun (Lond). 2018. PMID: 29764506 Free PMC article.
-
Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.Curr Oncol Rep. 2016 Jun;18(6):35. doi: 10.1007/s11912-016-0521-1. Curr Oncol Rep. 2016. PMID: 27113369 Review.
-
Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.Interv Cardiol. 2019 May 21;14(2):89-94. doi: 10.15420/icr.2019.12. eCollection 2019 May. Interv Cardiol. 2019. PMID: 31178935 Free PMC article. Review.
-
Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel). 2023 Mar 30;16(4):510. doi: 10.3390/ph16040510. Pharmaceuticals (Basel). 2023. PMID: 37111268 Free PMC article. Review.
-
Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.Drug Saf. 2022 Feb;45(2):101-126. doi: 10.1007/s40264-021-01132-5. Epub 2022 Jan 13. Drug Saf. 2022. PMID: 35025085 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials